top of page

Steroid Congress Scientific Program

Steroid Congress 2023 is Co-Organized by

 Dr Trevor M. Penning, Editor In Chief of Steroids 


Dr Jerzy Adamski, Editor in Chief of the Journal of Steroid Biochemistry and Molecular Biology

In partnership with Elsevier

Bellow is the conference program for Steroid Congress 2023, this schedule may be subject to changes due to unforeseen circumstances and limitations in speaker availability. 

You may register for the Congress via the button below.

*Steroid Congress 2023 has limited registration availability, register now to reserve your spot

Friday October 6, 2023

Opening Remarks

Opening Remarks from co-congress organizer and Editor in Chief of Steroid Biochemistry and Molecular Biology, Jerzy Adamski


Session organized by Sheng-Xian Lin, University Laval, Québec Canada

  • Steroid derivatives as therapeutic tools for intracrinology – Donald Poirier, CHU de Québec Research Center, Université Laval, Canada 

  • Interaction of steroid enzymes contributing to intracrinology – X. Lin, Université Laval, Canada

  • 11-oxygenated androgens in cancer – Chantal Guilmere, Université Laval, Canada

  • The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression – Étienne Audet-Walsh, Department of Molecular Medicine, Faculty of Medicine, Université Laval, Canada

  • Relevance of intra-adipose tissue steroid metabolism in human obesity and associated cardiometabolic alterations – André Tchernof, Canada

Steroid Analytics, Population Steroidomics, New Steroids 

  • Pediatric Steroid Diagnostics  Stefan Wudy, Justus Liebig University, Giessen, Germany

  • Bringing mass spectrometry-based diagnostic panels into adrenal disorders  Man-Ho Choi, Korea Institute of Science and Technology, Seoul, Korea

  • Challenges in measuring estrogens and androgens by LC-MS  Clementina Mesaros, University of Pennsylvania, Philadelphia, USA

  • Longitudinal analysis of blood biomarkers and glucocorticoid dosing from children within the I-CAH Registry  Neil Lawrence, Sheffield University, UK

Poster Presentations

Poster presentations by early stage investigators

Glucocorticoid Receptor as a Therapeutic Target

  • Long term effects of glucocorticoid therapies and some strategies to reduce them  Onno Meijer, Leiden University Medical Center, Leiden, The Netherlands

  • Glucocorticoid Receptor Crosstalk as One Way to Alleviate Side Effects  Karolien De Bosscher, Gent University, Gent, Belgium

  • Insights on anti-inflammatory effects of glucocorticoids and HPA axis regulation in COVID-19 disease  Elena Chetrok Shacham, Emek Medical Center, Afula, Israel

  • NfKb, interferon regulation  John Cidlowski, NIEHS, USA

Saturday October 7, 2023

Structural Biology of Steroid Receptors

  • AR dimerization modes: evidence from crystals to animal models  Frank K. Claessens, University of Leuven, Leuven, Belgium 

  • From Steroids to Shape Shifting - how the Androgen Receptor is Primed to Drive Cancer Elizabeth Wasmuth, University of Texas Health at San Antonio, USA

  • Domain-domain interactions within nuclear receptors  Fraydoon Rastinejad, University of Oxford, Oxford, UK

Novel Steroid Receptor Ligands

  • Small Molecule Inhibitors of Androgen Receptor N-Terminus Domain for the Treatment of Splice Variant-Positive Prostate Cancer – Ramesh Narayanan University of Tennessee Health Science Center, Memphis, USA 

  • PROTACS for Nuclear Receptors  Shaomeng Wang, University of Michigan, USA 

  • Photoswitched Remotely Tethered Ligands (PORTL)  Dirk Trauner, University of Pennsylvania, USA 

  • Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer  Marianne D. Sadar, BC Cancer, Vancouver, Canada

Mechanisms of Action of Vitamin D

  • Molecular mechanisms of vitamin D signalling in the thymus: implications for autoimmunity – John H. White, McGill University, Montreal, Canada

  • Vitamin D toxicity  Glen Jones, Canada

  • Vitamin D fortification – Kevin Cashman, Cork, Ireland

  • Therapeutic Potential of a Novel Vitamin D3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding – Andrea Stringer , Australia

New Steroids on the Block-11-Oxygenated Androgens

  • 11-oxyandrogens co-secreting cortisol tumors – Juilee Rege, University of Michigan, Ann Arbor, USA

  • Regulation of 11-oxyandrogen production – Richard Auchus, University of Michigan, USA 

  • Biosynthesis, metabolism and activity of 11-oxygenated sex steroids – Karl Storbeck, Stellenbosch University, South Africa

  • 11-Oxygenated androgens in health and disease – Adina Turcu, University of Michigan, USA

  • Classic and 11-oxygenated androgens in serum and saliva across adulthood: a cross-sectional study analyzing the impact of age, body mass index, and diurnal and menstrual cycle variation – Lina Schiffer, Cleveland Clinic Lerner Research Institute, USA 

Sunday October 8, 2023

Molecular Phenotyping in Health and Disease

  • Rare monogenic disorders impacting steroidogenesis – Tülay Guran, Marmara University, Istanbul, Turkey

  • Monogenic Disorders of Adrenal Steroidogenesis – Elisabeth Baranowski, Birmingham, UK 

  • 17-beta-HSD3 Deficiency – Je Qiao, China

  • HSD17B3 Mutations, genetic penetrance and phenotypes – Alex Odermatt, Switzerland

  • Sex differences in skeletal and hepatic (patho)physiology: role of sex hormone receptors – Vanessa Dubois. Ghent University, Gent, Belgium

Mechanisms of drug resistance in cancer therapies

  • Mechanisms of Drug Resistance in Castrate Resistant Prostate Cancer – Nima Sharifi, Cleveland Clinic, USA

  • Enzalutamide and Abiraterone Drug Resistance – Allen Gao, UC Davis, USA  

  • Androgen receptor splice variants – Stephen Plymate, Fred Hutchinson Cancer Center, Seattle, USA

  • Spatial transcriptomics and single-cell analyses of estrogen receptor-positive breast cancer – Shiuan Chen, City of Hope, USA

Closing Remarks

Closing remarks from the co-congress organizer and Editor in Chief of Steroids, Trevor M. Penning

bottom of page